ArticleFrontiers in cellular and infection microbiology2023
Combined analysis of gut microbiome and serum metabolomics reveals novel biomarkers in patients with early-stage non-small cell lung cancer.
Article in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The composition alteration of gut microbiota in lung cancer: a systematic review and meta-analysis.Frontiers in microbiology · 2026Pooled it
- Sphingolipids in human disease: organ-specific pathologies, chain-length-dependent effects, and translational implications.Journal of translational medicine · 2026Review
- Radiomics features combined with clinical and CT features for predicting the Ki-67 index in stage T1 non-small cell lung cancer patients: a multicenter study.Journal of thoracic disease · 2026Article
- The Dynamic Gut Microbiota: Monitoring Alterations During Lung Cancer Progression for Diagnosis and Precision Medicine.International journal of molecular sciences · 2026Review
- Urinary Volatilomic Signatures for Non-Invasive Detection of Lung Cancer: A HS-SPME/GC-MS Proof-of-Concept Study.International journal of molecular sciences · 2026Article
- From gut to lung: Microbiota-derived metabolites reshaping the tumor immune microenvironment.EXCLI journal · 2026Article
- Gut-Lung Microbiota Axis Shapes the Immune Microenvironment and Immunotherapeutic Response in Lung Cancer.International journal of biological sciences · 2026Review
- Dynamic changes and clinical significance of the gut microbiota and serum metabolites in breast cancer onset, progression and chemotherapy intervention.Frontiers in oncology · 2026Article
- Salivary metabolic profile landscape for gastric cancer screening: a metabolomic approach.Cancer cell international · 2025Article
- The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment.Cellular oncology (Dordrecht, Netherlands) · 2025Review
- Ginseng Polysaccharides InhibitCancers · 2025Article
- Characteristics of gut and lung microbiota in patients with lung masses and their relationship with clinical features.BMC microbiology · 2025Article
- Polysaccharides derived from Rosa rugosa cv. Plena ameliorate colorectal cancer by regulating intestinal microbiota composition and lipid metabolism pathway.NPJ science of food · 2025Article
- Airway microbiota associated D-phenylalanine promotes non-small cell lung cancer metastasis through epithelial mesenchymal transition.Journal of translational medicine · 2025Article
- Sphingolipid metabolism dysregulation: A cause for lung cancer development, progression, and resistance to therapies.Chinese medical journal pulmonary and critical care medicine · 2025Review
- Machine learning-derived diagnostic model of epithelial ovarian cancer based on gut microbiome signatures.Journal of translational medicine · 2025Article
- Gut microbiota and metabolites: emerging prospects in the treatment of non-small cell lung cancer.Frontiers in immunology · 2025Review
- Unravelling the prognostic and operative role of intratumoural microbiota in non-small cell lung cancer: Insights from 16S rRNA and RNA sequencing.Clinical and translational medicine · 2025Article
- Integrative multi-omics analysis of the microbiome and metabolome in bronchoalveolar lavage fluid from patients with early-stage lung cancer.Frontiers in cellular and infection microbiology · 2025Article
- Metabolomics for early-stage lung adenocarcinoma: diagnostic biomarker screening.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer and is one of the most fatal cancers worldwide. Recently, the International Association for the Study of Lung Cancer (IASLC) proposed a novel grading system based on the predominant and high-grade histological patterns for invasive pulmonary adenocarcinoma (IPA). To improve outcomes for NSCLC patients, we combined serum metabolomics and fecal microbiology to screen biomarkers in patients with early-stage NSCLC and identified characteristic microbial profiles in patients with different grades of IPA. 26 genera and 123 metabolites were significantly altered in the early-stage NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.